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The beneﬁcial eﬀects of dexmedetomidine (DEX) have not been extensively investigated in elderly 
patients receiving spinal anesthesia.  This study evaluated the eﬀects of intravenous DEX infusion on 
stress and hemodynamic response,  as well as on postoperative analgesia in elderly patients undergoing 
total knee arthroplasty (TKA).  We randomly allocated 45 adult patients to 3 patient groups (n＝15 
each): uni-saline group patients underwent unilateral TKA with saline administration,  uni-DEX group 
patients underwent unilateral TKA with DEX administration,  and bilateral-DEX group patients under-
went bilateral TKA with DEX administration.  Serum interleukin︲6 (IL︲6) levels were signiﬁcantly 
lower in the bilateral-DEX group than in the uni-saline group 6 and 24h postoperatively,  and were 
negatively correlated with total DEX dosage 24h postoperatively.  Bradycardia occurred more fre-
quently in the uni-DEX and bilateral-DEX groups than in the uni-saline group.  The total dose of 
required supplementary analgesics was signiﬁcantly higher in the uni-saline group than in the uni-DEX 
and bilateral-DEX groups 6h postoperatively.  The results indicate that perioperative intravenous DEX 
administration decreases postoperative serum IL︲6 levels in patients undergoing bilateral TKA,  and 
has a postoperative analgesic eﬀect in patients undergoing unilateral or bilateral TKA.
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U nlike previously employed sedatives such as midazolam and propofol,  which are primarily 
inhibitors of γ-aminobutyric acid (GABA) receptors,  
dexmedetomidine (DEX) acts on α2-adrenergic recep-
tors and induces adequate sedation without respiratory 
depression ﹇1︲3﹈.  The US Food and Drug Adminis-
tration (FDA) approved the use of DEX in humans at 
the end of 1999 as a short-term (less than 24h) analge-
sic and sedation medication in the intensive care unit 
﹇4﹈.  This sedative also produces analgesia by aﬀect-
ing the central nervous system,  and thereby reduces 
opioid requirements during and after surgery ﹇5,  6﹈.  
It has been reported that DEX decreases the release 
of stress response biomarkers ﹇7﹈,  and suppresses the 
sympathetic tone in a dose-dependent manner,  result-
ing in a considerable decrease in heart rate,  systemic 
blood pressure,  and cardiac output ﹇8︲10﹈.
　 Previous studies have reported that intravenous 
DEX administration extends the duration of spinal 
anesthesia,  and can provide postoperative analgesia 
﹇11,  12﹈.  However,  no study has evaluated the main-
tenance of hemodynamic stability and the postopera-
tive stress response in elderly patients receiving spinal 
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anesthesia.  This study was conducted to assess the 
hemodynamic changes and the extent of sedation asso-
ciated with DEX administration in elderly patients 
undergoing total knee arthroplasty (TKA).  In addition,  
we aimed to determine the beneﬁcial eﬀects of the use 
of intraoperative DEX during postoperative recovery,  
by examining its eﬀects on the reduction of stress 
response and induction of analgesia.
Methods
　 After obtaining approval from the Institutional 
Review Board,  we designed and conducted a random-
ized prospective,  controlled clinical study between 
June 2013 and April 2014 IRB of Jeju National 
University Hospital (IRB No. 2013︲05︲012).
　 Patients. Written informed consent was 
obtained from all patients.  Forty-ﬁve adult patients 
with physical status I and II according to the American 
Society of Anesthesiologists (ASA) who underwent 
TKA under spinal anesthesia were evaluated.  Patients 
with a history of diabetes,  severe cardiovascular dis-
ease,  steroid use,  renal or hepatic dysfunction,  men-
tal retardation,  pregnancy,  and preoperative hypoten-
sion or hypovolemia were excluded.
　 Group assessment. Patients were randomly 
assigned to 3 groups: a uni-saline group (n＝15; uni-
lateral TKA with saline administration); uni-DEX 
group (n＝15; unilateral TKA with DEX administra-
tion of 0.4︲0.8μg/kg/h); or bilateral-DEX group 
(n＝15; bilateral TKA with DEX administration of 
0.4︲0.8μg/kg/h).
　 Anesthetic regiment. All patients were admit-
ted to the operating room without premedication; they 
underwent noninvasive blood pressure monitoring,  
electrocardiography,  and pulse oximetry.  Hemodynamic 
parameters were recorded intraoperatively at 5min 
intervals.  After measuring the initial vital signs,  uni-
DEX and bilateral-DEX group patients were adminis-
tered an intravenous injection of DEX at 0.4μg/kg/h 
to a maximum of 0.8μg/kg/h (without a loading dose),  
together with oxygen at 5L/min through a mask.  DEX 
was injected until the surgical tourniquet was removed 
from the leg.  A similar protocol was carried out for 
saline group patients,  with the administration of saline 
and oxygen.  The dose of intraoperative DEX was 
adjusted to maintain a Ramsay sedation score of 3 ﹇13﹈.
　 Spinal anesthesia was induced at the L4-5 or L3︲4 
intervertebral spaces using 100μg epinephrine and 
added to 10mg bupivacaine HCl (AstraZeneca, Australia). 
Surgery was started when a bilateral sensory blockade 
was achieved up to the T10 dermatome.  No additional 
sedatives or analgesics were used during anesthesia or 
surgery.
　 Once patients were conﬁrmed as stable following 
anesthetic induction,  the end-tidal carbon dioxide 
(EtCO2) was monitored.  Apnea was suspected when 
EtCO2 was not detected for 20 sec or more during 
sedation.  Systolic blood pressure (SBP) was main-
tained within 20  of baseline; when SBP was equal 
to or less than 90mmHg,  5mg ephedrine was adminis-
tered intravenously.  Bradycardia was deﬁned as a 
heart rate of 50beats/min or less; in cases of brady-
cardia,  0.5mg atropine was administered intrave-
nously.
　 Postoperative pain was managed using a patient-
controlled analgesia (PCA) device containing 10μg/kg 
fentanyl and 300mg ketorolac mixed with 30mg ramo-
setron to a total volume of 100mL (1mL/h basal,  
1mL bolus,  and lockout time 15min,  intravenously).  
Pain was assessed using the visual analogue scale;  
when the score was 5 or more,  50mg tramadol was 
administered intravenously at the ward.
　 Measurements. Electrocardiogram,  non-inva-
sive blood pressure,  peripheral capillary oxygen satu-
ration,  and EtCO2 were monitored continuously during 
surgery at 5min intervals.  Postoperative pain was 
evaluated based on the total PCA volume adminis-
tered 6 and 24h postoperatively and the supplemen-
tary analgesics administered within 6h postopera-
tively.  Hormonal stress response was evaluated and 
compared by measuring serum concentrations of 
interleukin︲6 (IL︲6); serum samples were collected 
preoperatively as well as at 6 and 24h postoperatively.
　 Analysis. In a previous study,  the mean serum 
concentration of IL︲6 was shown to increase by a mean 
of 34.75±11.97pg/mL at 6h postoperatively in the 
control group,  but was unchanged in the DEX-treated 
group at this time point ﹇7﹈.  IL︲6 is a stress indica-
tor that peaks 4︲6h postoperatively.  Assuming that 
the observed increase at 6h postoperatively in the 
present study was similar to the trend observed in the 
aforementioned study,  when comparing the time-
dependent responses in the treatment group,  the 
required sample size for an alpha error of 0.05 and a 
beta error of 0.2 would be 15 subjects per group.
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　 All data were analyzed using SPSS software (IBM 
SPSS statistics 21 for Windows).  Among the continu-
ous categorical data,  normally distributed data were 
expressed as the mean ± standard deviation,  and non-
normally distributed data as the median value ﹇25th︲
75th percentile﹈.  Continuous data between groups 
were compared using Mann︲Whitney U and Kruskal︲
Wallis tests.  Non-continuous data between groups 
were analyzed using Fisherʼs exact test.  A Wilcoxon 
test was used to analyze values that changed from 
baseline,  and repeated measures analysis of variance 
(rANOVA) was used to analyze time-dependent hemo-
dynamic variables and stress response values.  Values 
of ｐ＜0.05 were considered statistically signiﬁcant.
Results
　 Demographic and clinical data were similar among 
the three groups.  The mean patient age was 70 years 
or older.  The median surgical and anesthetic dura-
tions were signiﬁcantly longer in the bilateral-DEX 
group than in the other groups.  The total dose of DEX 
administered was signiﬁcantly higher in the bilateral-
DEX group compared to the uni-DEX group (Table 1).  
When anesthesia was below dermatome T10,  patients 
were allowed to leave the recovery room.  There were 
no signiﬁcant diﬀerences in recovery time among groups.
　 In all groups,  the concentration of the stress 
response biomarker IL︲6 was signiﬁcantly diﬀerent 
from the preoperative baseline value within groups.  
The diﬀerences between the 3 groups became statisti-
cally signiﬁcant over time (Table 2).  Serum IL︲6 
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Table 1　 Demographic distribution and perioperative parameters
Uni-saline group
(n＝15)
Uni-DEX group
(n＝15)
Bilateral-DEX group
(n＝15)
Age (years) 73.9±3.8 72.5±6.4 69.9±3.9
Height (cm) 150.9±6.3 152.2±5.7 153.9±6.7
Weight (kg) 62.6±8.8 64.5±6.2 61.3±7.4
HTN, n (%) 11 (73.3) 11 (73.3) 7 (46.7)
SBP (mmHg) 128.8±16.4 132.0±10.1 132.1±14.3
DBP (mmHg) 75.7±7.6 79.5±8.4 78.1±8.5
HR (beats/min) 64.2±5.9 67.1±7.8 65.7±8.7
IL︲6 (pg/mL) 1.0±1.0 0.9±1.2 0.5±0.8
Duration of surgery (min),  median ﹇IQR﹈ 69.0 ﹇63.0︲78.0﹈ 65.0 ﹇59.0︲70.0﹈ 155.0 ﹇143.0︲168.0﹈＊†
Duration of anesthesia (min),  median ﹇IQR﹈ 110.0 ﹇100.0︲115.0﹈ 95.0 ﹇90.0︲110.0﹈ 205.0 ﹇180.0︲215.0﹈＊†
Total dose of DEX (µg) 0 40.3±10.5＊ 99.7±19.0＊†
Uni-saline group: unilateral total knee arthroplasty with saline administration.  Uni-DEX group: unilateral total knee arthroplasty with dex-
medetomidine administration.  Bilateral-DEX group: bilateral total knee arthroplasty with dexmedetomidine administration.  HTN,  hypertension;  
SBP,  systolic blood pressure; DBP,  diastolic blood pressure; HR,  heart rate; IL︲6,  interleukin︲6; IQR,  interquartile range; DEX,  dexme-
detomidine.  Data are presented as the mean ± SD or median ﹇IQR﹈.  ＊ｐ＜0.05 vs. the Uni-saline group;†ｐ＜0.05 vs. the Uni-DEX group.
Table 2　 Comparison of serum interleukin-6 levels among the 3 groups
Uni-saline group
(n＝15)
Uni-DEX group
(n＝15)
Bilateral-DEX group
(n＝15)
Interleukin︲6 (pg/mL)
　Basal 1.0±1.0 0.9±1.2 0.5±0.8
　PO 6h 52.5±23.5 47.4±11.8 35.8±22.7＊
　PO 24h 84.1±32.2 78.5±17.1 50.7±25.3＊
Uni-saline group: unilateral total knee arthroplasty with saline administration.  Uni-DEX group: unilateral total knee arthroplasty with dex-
medetomidine administration.  Bilateral-DEX group: bilateral total knee arthroplasty with dexmedetomidine administration.  Basal: preoperative 
serum level; PO 6h and 24h: 6h and 24h postoperatively.  Data are presented as the mean ± SD.  ＊ｐ＜0.05 vs. the Uni-saline group.
levels were signiﬁcantly lower in the bilateral-DEX 
group than in the uni-saline group at 6 and 24h post-
operatively (ｐ＝0.010,  0.005,  respectively).  When 
the association between changes in the total DEX dose 
and serum IL︲6 concentration was examined,  a sig-
niﬁcant negative correlation was observed in the val-
ues obtained 24h postoperatively (ｐ＝0.008,  Fig.  1).  
This relation is expressed by the following equation:
﹇IL︲6﹈＝－0.46×(total DEX dosage)＋97.75.
　 The lowest mean SBP was maintained in the uni-
saline group.  Intraoperatively,  the heart rate in the 
uni-DEX and bilateral-DEX groups remained lower 
than that in the uni-saline group; the diﬀerences 
between groups were not signiﬁcant (Fig.  2).  Apnea 
did not occur in either group as a secondary eﬀect to 
drug administration.  Two cases of hypotension were 
observed in each group,  and no signiﬁcant diﬀerences 
were observed among the 3 groups.  Bradycardia 
occurred more frequently in the uni-DEX and bilat-
eral-DEX groups than in the uni-saline group (ｐ＝
0.048,  0.014,  respectively; Table 3).
　 To determine the analgesic eﬀect of DEX,  total 
PCA volume administered postoperatively as well as 
supplementary analgesic requirements were compared 
among groups.  There were no signiﬁcant diﬀerences 
among the 3 groups in total PCA volume.  However,  
supplementary analgesic requirements 6h after sur-
gery due to a pain score higher than 5 were signiﬁ-
cantly higher in the uni-saline group than in the uni-
DEX and bilateral-DEX groups (ｐ＝0.048,  0.042,  
respectively; Table 4).
Discussion
　 In this study,  a signiﬁcant negative correlation was 
observed between the serum IL︲6 concentration,  which 
is a stress response biomarker,  and total DEX dose 
24h postoperatively.  There was no signiﬁcant decrease 
of SBP,  even when the duration of DEX administra-
tion was increased from its minimum rate of 0.4μg/
kg/h to a maximum of 0.8μg/kg/h.  Perioperative 
intravenous DEX administration produced a postop-
erative analgesic eﬀect,  without serious complications.
　 To determine whether the stress response was 
decreased,  IL︲6 concentrations were measured post-
operatively and compared to baseline levels in the 3 
groups.  IL︲6 is an immune mediator that can be 
detected 60min after injury; it peaks after 4︲6h,  and 
can be continuously detected up to 10 days ﹇14﹈.  
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Fig. 1　 Serum interleukin-6 concentration in relation to total dexmedetomidine dose in patients administered dexmedetomidine.  A sig-
niﬁcant negative correlation was observed between the total infusion dose of dexmedetomidine and serum interleukin︲6 levels 24h postop-
eratively (r＝－0.46,  ｐ＝0.008).  PO 6h and 24h: 6h and 24h postoperatively in the group administered dexmedetomidine.
Levels of the cytokine IL︲6 increase in response to 
acute psychological stress even in healthy adults,  and 
its circulating levels have been positively correlated 
with feelings of anger and anxiety ﹇15︲17﹈.  In a pre-
vious study,  unlike in the DEX group,  IL︲6 levels in 
the saline group increased two-fold compared to base-
line at 1d postoperatively ﹇7﹈.  In contrast,  other 
studies reported no signiﬁcant diﬀerences ﹇18,  19﹈.  
In this study,  the IL︲6 concentrations at 6 and 24h 
postoperatively diﬀered signiﬁcantly between the 
bilateral-DEX and uni-saline groups (Table 2).  Because 
the total dose of DEX administered diﬀered between 
these groups,  IL︲6 changes associated with the total 
DEX dose were analyzed.  A negative correlation was 
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Fig. 2　 Intraoperative changes (5min intervals) in heart rate and systolic blood pressure after intravenous infusion of dexmedetomidine.  
Uni-saline group (black line  ): unilateral total knee arthroplasty with saline administration.  Uni-DEX group (gray line  ): unilat-
eral total knee arthroplasty with dexmedetomidine administration.  Bilateral-DEX group (gray dotted line  ): bilateral total knee 
arthroplasty with dexmedetomidine administration.  Data are presented as the mean ± SD.
Table 3　Distribution of side eﬀects
Uni-saline group
(n＝15)
Uni-DEX group
(n＝15)
Bilateral-DEX group
(n＝15)
0 (0) 0 (0) 0 (0)
2 (13.3) 2 (13.3) 2 (13.3)
1 (6.7) 5 (33.3)＊ 8 (53.3)＊
Uni-saline group: unilateral total knee arthroplasty with saline 
administration.  Uni-DEX group: unilateral total knee arthroplasty 
with dexmedetomidine administration.  Bilateral-DEX group: bilateral 
total knee arthroplasty with dexmedetomidine administration.  Data 
are presented as the number of patients (percentage).  ＊ｐ＜0.05 
vs. the Uni-saline group.
observed,  suggesting a decreased stress response 
(Fig.  1).
　 The sedative DEX targets the presynaptic α2- 
adrenergic receptor,  and through negative feedback 
controls the secretion of epinephrine,  inhibiting sym-
pathetic activity and decreasing blood pressure and 
heart rate ﹇4,  8,  20﹈.  In contrast to a previous study 
﹇21﹈ that reported a dose-dependent decline in blood 
pressure,  in the present study,  no patient showed a 
decrease in blood pressure,  even when the dose of 
DEX was increased to a maximum of 0.8μg/kg/h.  
However,  bradycardia occurred in both the uni-DEX 
and bilateral-DEX groups,  which is consistent with the 
results of previous studies.
　 The activation of dorsal horn α2-adrenergic recep-
tors reduces the secretion of the nociceptive neu-
rotransmitter substance P,  producing primary analge-
sia ﹇22﹈.  The locus ceruleus is the origin of the 
descending medullo-spinal noradrenergic pathway,  
which plays an important role in the regulation of 
analgesia.  DEX is known to extend the time to the 
ﬁrst postoperative analgesic request ﹇12,  23,  24﹈.  
This analgesic eﬀect is not dose-dependent,  and a 
ceiling eﬀect occurs at a dose higher than 0.5μg/kg 
﹇25﹈.  Our study compared the requirements for sup-
plementary analgesia within 6h postoperatively.  In the 
uni-DEX and bilateral-DEX groups,  postoperative 
pain was managed solely with PCA,  except in the case 
of one subject.  Five subjects in the control group 
required additional analgesia,  which was a statisti-
cally signiﬁcant diﬀerence (Table 4).  
　 This study had some limitations.  The sample size 
was small,  and the experimental bilateral-DEX group 
lacked an appropriate saline group,  which would 
include subjects undergoing bilateral TKA with saline 
administration.  However,  because bilateral TKA 
requires more than 2h of surgery,  a sedative agent 
(ｅ．ɡ．,  midazolam or propofol) is usually given to reduce 
patient discomfort.  In addition,  this study used the 
recommended continuous infusion dose without a load-
ing dose.  However,  administration of DEX may cause 
hemodynamic instability.  In elderly patients who are 
susceptible to blood pressure changes,  the initial load-
ing dose may increase the risk of hemodynamic 
complications; therefore,  future research must focus 
on a continuous infusion protocol without a loading 
dose ﹇20,  26﹈.
　 In those undergoing TKA under spinal anesthesia,  
DEX resulted in a low incidence of adverse eﬀects 
such as apnea or hypotension,  while maintaining ade-
quate sedation.
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